Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants

References

• Centers for Disease Control and Prevention. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States; 2018 [accessed 2018 March 23]. https://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html
   Google Scholar
• European Centre for Disease Prevention and Control. Vaccine scheduler: vaccine schedules in all countries of the European Union. [accessed 2018 March 23]. https://vaccine-schedule.ecdc.europa.eu/.
   Google Scholar
• Melville JM, Moss TJ. The immune consequences of preterm birth. Front Neurosci. 2013;7:79. doi:10.3389/fnins.2013.00079.
   PubMed Web of Science ®Google Scholar
• Gagneur A, Pinquier D, Quach C. Immunization of preterm infants. Hum Vaccin Immunother. 2015;11(11):2556–63. doi:10.1080/21645515.2015.1074358.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2019 global summary. [accessed 2019 December 6]. http://apps.who.int/immunization_monitoring/globalsummary/schedules.
   Google Scholar
• Wilson K, Hawken S, Holdt Henningsen K, Kwong JC, Deeks SL, Crowcroft NS, Law B, Manuel DG. On-time vaccination coverage in premature infants in Ontario, 2002–2009. Can J Public Health. 2012;103:e359–62. doi:10.1007/BF03404441.
   PubMed Web of Science ®Google Scholar
• McCrossan P, McCafferty C, Murphy C, Murphy J. Retrospective review of administration of childhood primary vaccination schedule in an Irish tertiary neonatal intensive care unit. Public Health. 2015;129:896–98. doi:10.1016/j.puhe.2015.05.005.
   PubMed Web of Science ®Google Scholar
• Sánchez PJ, Laptook AR, Fisher L, Sumner J, Risser RC, Perlman JM. Apnea after immunization of preterm infants. J Pediatr. 1997;130(5):746–51. doi:10.1016/S0022-3476(97)80017-0.
   PubMed Web of Science ®Google Scholar
• Botham SJ, Isaacs D. Incidence of apnoea and bradycardia in preterm infants following triple antigen immunization. J Paediatr Child Health. 1994;30(6):533–35. doi:10.1111/j.1440-1754.1994.tb00728.x.
   PubMed Web of Science ®Google Scholar
• Pfister RE, Aeschbach V, Niksic-Stuber V, Martin BC, Siegrist CA. Safety of DTaP-based combined immunization in very-low-birth-weight premature infants: frequent but mostly benign cardiorespiratory events. J Pediatr. 2004;145(1):58–66. doi:10.1016/j.jpeds.2004.04.006.
   PubMed Web of Science ®Google Scholar
• Klein NP, Massolo ML, Greene J, Dekker CL, Black S, Escobar GJ, Datalink VS. Risk factors for developing apnea after immunization in the neonatal intensive care unit. Pediatrics. 2008;121(3):463–69. doi:10.1542/peds.2007-1462.
   PubMed Web of Science ®Google Scholar
• Langkamp DL, Hoshaw-Woodard S, Boye ME, Lemeshow S. Delays in receipt of immunizations in low-birth-weight children: a nationally representative sample. Arch Pediatr Adolesc Med. 2001;155(2):167–72. doi:10.1001/archpedi.155.2.167.
   PubMedGoogle Scholar
• Vázquez L, Garcia F, Rüttimann R, Coconier G, Jacquet JM, Schuerman L. Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants. Acta Paediatr. 2008;97(9):1243–49. doi:10.1111/j.1651-2227.2008.00884.x.
   PubMed Web of Science ®Google Scholar
• Munoz A, Salvador A, Brodsky NL, Arbeter AM, Porat R. Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer membrane protein conjugate vaccine. Pediatrics. 1995;96:216–19.
   PubMed Web of Science ®Google Scholar
• Kristensen K, Gyhrs A, Lausen B, Barington T, Heilmann C. Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J. 1996;15(6):525–29. doi:10.1097/00006454-199606000-00010.
   PubMed Web of Science ®Google Scholar
• Slack MH, Schapira D, Thwaites RJ, Burrage M, Southern J, Andrews N, Borrow R, Goldblatt D, Miller E. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. J Infect Dis. 2001;184(12):1617–20. doi:10.1086/324666.
   PubMed Web of Science ®Google Scholar
• Marshall GS, Adams GL, Leonardi ML, Petrecz M, Flores SA, Ngai AL, Xu J, Liu G, Stek JE, Foglia G, et al. Immunogenicity, safety, and tolerability of a hexavalent vaccine in infants. Pediatrics. 2015;136(2):e32332. doi:10.1542/peds.2014-4102.
   Web of Science ®Google Scholar
• Lee AW, Jordanov E, Boisnard F, Marshall GS. DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers. Expert Rev Vaccines. 2017;16(2):85–92. doi:10.1080/14760584.2017.1268920.
   PubMed Web of Science ®Google Scholar
• Vaxelis [package insert]. Leiden (The Netherlands): MCM Vaccine B.V. [accessed 2018 Mar 23]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003982/WC500202435.pdf
   Google Scholar
• Tapiéro B, Halperin SA, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee AW, et al. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study. Pediatr Infect Dis J. 2013;32(1):54–61. doi:10.1097/INF.0b013e3182717edf.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Tapiéro B, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee A, et al. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2014;33(1):73–80. doi:10.1097/01.inf.0000437806.76221.20.
   PubMed Web of Science ®Google Scholar
• Block SL, Klein NP, Sarpong K, Russell S, Fling J, Petrecz M, Flores S, Xu J, Liu G, Stek JE, et al. Lot-to-lot consistency, safety, tolerability and immunogenicity of an investigational hexavalent vaccine in US infants. Pediatr Infect Dis J. 2017;36(2):202–08. doi:10.1097/INF.0000000000001405.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months. Pediatr Infect Dis J. 2017;36(2):209–15. doi:10.1097/INF.0000000000001406.
   PubMed Web of Science ®Google Scholar
• Silfverdal SA, Icardi G, Vesikari T, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, et al. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 1112 months. Vaccine. 2016;34(33):3810–16. doi:10.1016/j.vaccine.2016.05.054.
   PubMed Web of Science ®Google Scholar
• Xu J, Stek JE, Ziani E, Liu GF, Lee AW. Integrated safety profile of a new approved, fully liquid DTaP-IPV-Hib-HepB vaccine. Pediatr Infect Dis J. 2019;38(4):439–43. doi:10.1097/INF.0000000000002257.
   PubMed Web of Science ®Google Scholar
• Infanrix hexa [package insert]. Rixensart (Belgium): GlaxoSmithKline Biologics s.a. [accessed 2018 Mar 23]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000296/WC500032505.pdf
   Google Scholar
• Pentacel [package insert]. Swiftwater (PA): Sanofi Pasteur Inc. [accessed 2018 Mar 23]. https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm109810.pdf.
   Google Scholar
• Marshall H, Clarke M, Rasiah K, Richmond P, Buttery J, Reynolds G, Andrews R, Nissen M, Wood N, McIntyre P. Predictors of disease severity in children hospitalized for pertussis during an epidemic. Pediatr Infect Dis J. 2015;34(4):339–45. doi:10.1097/INF.0000000000000577.
   PubMed Web of Science ®Google Scholar